Journal of Diagnostics Concepts & Practice >
A single-center retrospective clinical study of 7 cases of acquired hemophilia A
Received date: 2024-04-08
Accepted date: 2024-10-08
Online published: 2025-02-25
Objective This study aims to explore the etiology, clinical manifestations, diagnosis and treatment, and prognosis of acquired hemophilia A (AHA), and to improve the clinical understanding, diagnosis, and treatment of AHA. Methods A retrospective analysis was conducted on 7 cases of AHA diagnosed at our hospital from January 2013 to December 2023. Relevant literature was searched in PubMed, CNKI, and Wanfang databases using the terms “Acquired hemophilia A”. A comparative analysis was performed on general data, etiology, diagnosis time, clinical manifestations, treatment, and prognosis. Results All 7 AHA patients were female, with a median age of 44.1 years (range 26-68 years). One case was secondary to hepatitis B virus infection; one was secondary to pregnancy; one developed after gastrointestinal surgery; and one was secondary to Sjögren’s syndrome. Skin ecchymosis was the most common clinical manifestation of AHA(7/7), with increased activated partial thromboplastin time (APTT), decreased coagulation factor Ⅷ(FⅧ) activity (FⅧ:C), and increased FⅧ antibody (FⅧ: Ab). Six patients received hemostatic therapy, and all patients received antibody clearance therapy. The median follow-up time was 391 days (28-777 days), with one patient lost to follow-up. Four patients achieved complete response (CR), with a median time to CR of 40 days (27-48 days). One patient achieved partial response (PR), and no recurrence occurred. One patient had no response (NR) and no new clinical bleeding during the follow-up period. The literature review found that AHA can occur in both men and women, with a predominance of women of childbearing age. 56.8% of the patients had idiopathic AHA, while 11.4%, 11.1%, and 6.7% patients of AHA associated with tumors, autoimmune diseases, and pregnancy, respectively. The male to female ratio is 1.18:1, with median ages of 65.6 years and 55.8 years, respectively. Bypass pathway drugs were the first choice for hemostatic treatment, and antibody clearance therapy was mostly based on glucocorticoids, cyclophosphamide, and rituximab. Conclusions AHA can be secondary to tumors, autoimmune diseases, infections, pregnancy, etc. Patients may have skin bruising; The use of bypass routes for hemostasis and immunosuppressive therapy to clear antibodies results in a good prognosis for most patients.
Key words: Acquired hemophilia A; Diagnosis; Treatment
QIAN Lingling , PEI Xiaoping , SUN Aihong , HEI Bin , SUN Mei . A single-center retrospective clinical study of 7 cases of acquired hemophilia A[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(05) : 524 -530 . DOI: 10.16150/j.1671-2870.2024.05.009
[1] | COLLINS P W, HIRSCH S, BAGLIN T P, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation[J]. Blood, 2007, 109(5):1870-1877. |
[2] | TIEDE A, WAHLER S. The rising incidence of acquired haemophilia A in Germany[J]. Haemophilia, 2021, 27(4):e466-e468. |
[3] | PAI M. Acquired Hemophilia A[J]. Hematol Oncol Clin North Am, 2021, 35(6):1131-1142. |
[4] | DELGADO J, JIMENEZ-YUSTE V, HERNANDEZ-NAVARRO F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors[J]. Br J Haematol, 2003, 121(1):21-35. |
[5] | BAUDO F, COLLINS P, HUTH-KüHNE A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry[J]. Blood, 2012, 120(1):39-46. |
[6] | KNOEBL P, MARCO P, BAUDO F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)[J]. J Thromb Haemost, 2012, 10(4):622-631. |
[7] | SUN B, XUE F, FENG Y, et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China[J]. Br J Haematol, 2019, 187(5):653-665. |
[8] | 陈桂芳, 何芸, 刘叶, 等. 22例获得性血友病A患者的临床特点及预后[J]. 贵州医科大学学报, 2024, 49(8):1218-1223,1229. |
CHEN G F, HE Y, LIU Y, et al. Clinical features and prognosis of 22 patients with acquired hemophilia A[J]. J Guizhou Med Univ, 2024, 49(8):1218-1223,1229. | |
[9] | KAHLE J, ORLOWSKI A, STICHEL D, et al. Frequency and epitope specificity of anti-factor Ⅷ C1 domain antibodies in acquired and congenital hemophilia A[J]. Blood, 2017, 130(6):808-816. |
[10] | TIEDE A, HOFBAUER C J, WERWITZKE S, et al. Anti-factor Ⅷ IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study[J]. Blood, 2016, 127(19):2289-2297. |
[11] | TENGBORN L, BAUDO F, HUTH-KüHNE A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry[J]. BJOG, 2012, 119(12):1529-1537. |
[12] | KHAN U Z, YANG X, MASROOR M, et al. Surgery-associated acquired hemophilia A: a report of 2 cases and review of literature[J]. BMC Surg, 2020, 20(1):213. |
[13] | 刘凌, 冯莹, 谢玮, 等. 44例获得性血友病A的病因、临床表现及诊疗的探讨[J]. 血栓与止血学, 2018, 24(1):1-4. |
LIU L, FENG Y, XIE W, et al. The etiology, clinical manifestation,diagnosis and treatment effect in patients with acquired hemophilia-A[J]. Chin J Thromb Hemost, 2018, 24(1):1-4. | |
[14] | 周莉, 张馨慧, 冯尚龙, 等. rFⅦa联合强化免疫抑制治疗获得性血友病A的回顾性临床研究[J]. 血栓与止血学, 2021, 27(2):181-185. |
ZHOU L, ZHANG X H, FENG S L, et al. A retrospective clinical study of rFⅦa combined with immunosuppressive therapy in the treatment of acquired hemophilia A[J]. Chin J Thromb Hemost, 2021, 27(2):181-185. | |
[15] | 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 获得性血友病A诊断与治疗中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(10):793-799. |
Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association; Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the diagnosis and treatment of acquired hemophilia A (2021)[J]. Chin J Hematol, 2021, 42(10):793-799. | |
[16] | TIEDE A, COLLINS P, KNOEBL P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A[J]. Haematologica, 2020, 105(7):1791-1801. |
[17] | KRUSE-JARRES R, KEMPTON CL, BAUDO F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance[J]. Am J Hematol, 2017, 92(7):695-705. |
[18] | TIEDE A, KLAMROTH R, SCHARF R E, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study[J]. Blood, 2015, 125(7):1091-1097. |
[19] | HOLSTEIN K, LIU X, SMITH A, et al. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study[J]. Blood, 2020, 136(3):279-287. |
[20] | SHIMA M, AMANO K, OGAWA Y, et al. A prospective, multicenter, open-label phase Ⅲ study of emicizumab prophylaxis in patients with acquired hemophilia A[J]. J Thromb Haemost, 2023, 21(3):534-545. |
[21] | TIEDE A, HART C, KN?BL P, et al. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study[J]. Lancet Haematol, 2023, 10(11):e913-e921. |
[22] | OLDENBURG J, MAHLANGU J N, KIM B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors[J]. N Engl J Med, 2017, 377(9):809-818. |
[23] | COLLINS P, BAUDO F, KNOEBL P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)[J]. Blood, 2012, 120(1):47-55. |
[24] | 郭玉洁, 韩欢, 李笑, 等. 单中心25例获得性血友病A临床分析[J]. 中国实验血液学杂志, 2024, 32(6):1829-1833. |
GUO Y J, HAN H, LI X, et al. Clinical analysis of 25 cases of acquired hemophilia A in a single center[J]. J Exp Hematol, 2024, 32(6):1829-1833. | |
[25] | LIU W, LIU J, XUE F, et al. Anti-CD38 antibody for refractory acquired hemophilia A[J]. J Thromb Haemost, 2023, 21(6):1515-1518. |
/
〈 |
|
〉 |